[Skip to Content]
[Skip to Content Landing]
Comment & Response
August 4, 2020

Research and Development Costs of New Drugs—Reply

Author Affiliations
  • 1Department of Health Policy, London School of Economics and Political Science, London, United Kingdom
  • 2Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom
  • 3Department of Public Health and Primary Care, Leuven Institute for Healthcare Policy, Leuven, Belgium
JAMA. 2020;324(5):518. doi:10.1001/jama.2020.8651

In Reply The correspondents raise concerns about the nonrepresentativeness of our sample,1 which arose because we restricted ourselves to publicly available data. Other studies have relied on confidential data that companies agreed to share.2-4 To the best of our knowledge, none of the previous studies on this topic, including that by DiMasi et al,2 which involved only 10 midsized to large companies, are representative.

×